Resveratrol
CAS 501-36-0
Resveratrol (CAS 501-36-0) is a Phase 3 pharmaceutical compound with 12 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 33814.26885646438 nM | 375 | - |
| - | Potency | 17859.15175879397 nM | 117 | - |
| - | GI50 | 58271.93538461539 nM | 52 | - |
| - | Ki | 13408.3 nM | 30 | - |
| - | EC50 | 29047.931034482757 nM | 29 | - |
| - | MIC | 108.1853448275862 ug.mL-1 | 29 | - |
| - | IC50 | 20.8445 ug.mL-1 | 20 | - |
| - | GI50 | 5.25 ug.mL-1 | 18 | - |
| - | AC50 | 50318.520000000004 nM | 10 | - |
| - | Kd | 7732 nM | 7 | - |
| - | MIC | 298833.3333333333 nM | 3 | - |
| - | EC50 | 4.37 ug.mL-1 | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| COX-2 PTGS2 |
Inhibition | 6.119999885559082 pIC50 | 20527891 |
| Peroxisome proliferator-activated receptor-γ PPARG |
Antagonist | 5.849999904632568 pKd | 24796862 |
| TAS2R14 TAS2R14 |
Agonist | 4.519999980926514 pEC50 | 24117141 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| RESVERATROL | 1000492 | SU | MTHSPL |
| resveratrol | 1000492 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Resveratrol used for in pharmaceutical contexts?
Resveratrol (CAS 501-36-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Resveratrol?
No adverse-event association or SIDER side-effect rows are rendered for Resveratrol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Resveratrol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Resveratrol with EU status "permitted".
What clinical phase is Resveratrol in?
Resveratrol is rendered with ChEMBL max phase 3.